Precision targeting of the plasminogen activator inhibitor‐1 mechanism increases efficacy of fibrinolytic therapy in empyema

Plasminogen activator inhibitor‐1 (PAI‐1) is an endogenous irreversible inhibitor of tissue‐type (tPA) and urokinase (uPA) plasminogen activators. PAI‐1‐targeted fibrinolytic therapy (PAI‐1‐TFT) is designed to decrease the therapeutic dose of tPA and uPA, attenuating the risk of bleeding and other c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Physiol Rep
Autors principals: Florova, Galina, Girard, René A., Azghani, Ali O., Sarva, Krishna, Buchanan, Ann, Karandashova, Sophia, DeVera, Christian J., Morris, Danna, Chamiso, Mignote, Koenig, Kathleen, Cines, Douglas B., Idell, Steven, Komissarov, Andrey A.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8123555/
https://ncbi.nlm.nih.gov/pubmed/33991465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14814/phy2.14861
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars